Saturday 17 October 2026
Export VALN’s income statement to Excel — free account
Valneva SE Sponsored ADR
VALN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 17.3%, EPS fell 222.1%, free cash flow fell 56.1% and total debt rose 12.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
5.61
0.30
−5.08%
Follow VALN
| Jun '26 | Mar '26 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 2 | — | — |
+8 more TTM periods Free account |
| 0.00% | (11.99%) | 0.00% | 0.00% | ||
| 0.00% | (3.93%) | 0.00% | 0.00% | ||
ROIC |
0.00% | 7.73% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | (7.56%) | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 26.38 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.60) | 0.00 | 0.00 | |
Free Cash Flow |
(58.90) | (53.22) | (158.85) | (260.45) | |
Capital Expenditures |
(5.90) | (7.25) | (28.86) | (123.15) | |
| Other line items | |||||
Cash ROIC |
(13.10%) | (12.48%) | (29.44%) | (44.45%) | |
Accounts Receivable Turnover |
0.00 | 7.25 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 2.79 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 1.65 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 91.97 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 213.35 | 0.00 | 0.00 | |
Tax Rate |
— | 0.37 | — | — | |
Research and Development Expense of Revenue |
— | 39.67% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 55.35% | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Interest Coverage |
— | 1.10 | — | — | |
Operating CF/Net income |
0.00 | 2.33 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.35 | 0.00 | 0.00 | 0.31 | |
Capex/Depreciation |
(0.13) | 0.00 | 0.00 | (2.76) | |
Revenue per Share |
— | 1.84 | — | — | |
Operating CF per Share |
0.00 | (0.52) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.08) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.00 | 0.00 |
Columns are period end dates